At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 41 enrolled

Drug / intervention

Guanfacine +1 moredrug

Likely dose

Guanfacine 1mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02699125

NCT02699125Phase 4Completed

Compare CT.gov

A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension

University of California, San Diego·interventional·Posted Mar 4, 2016·Updated Dec 4, 2020

In Brief

A Phase 4 clinical trial evaluating Guanfacine and Hydrochlorothiazide for Obstructive Sleep Apnea. Completed, enrolled 41 participants.

Detailed Summary

Patients who have obstructive sleep apnea (OSA) frequently stop breathing while they sleep. They often develop high blood pressure. We are not sure what drug is best to treat the high blood pressure. This study will give the patients guanfacine or hydrochlorothiazide (HCTZ) for 6 weeks after 2 weeks of placebo. The blood pressure response will be evaluated by 24 hour monitoring.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsObstructive Sleep Apnea

Countries--

Collaborators--

Timeline

Phase 4CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartJan 2015

First PostedMar 2016

Primary CompletionJun 2016

Study CompletionAug 2016

TodayJul 2026

First PostedMar 4, 2016

Enrollment StartJan 1, 2015

Primary CompletionJun 1, 2016

Study CompletionAug 1, 2016

TodayJul 2, 2026

Enrollment to primary: 1.4 yearsPosted 10.3 years ago

Interventions

Guanfacinedrug

Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.

Hydrochlorothiazidedrug

Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks